More Videos
- Johnson & Johnson Makes Dollars--And Stents
- Genentech's Avastin Goes Primetime
- Genentech Regains "Title" As Best Biopharma Employer
- The Last Word--For Now--On Dendreon
- Barack Obama: Big Pharma's Million Dollar Man
- Roche Speaks My Language But Genentech Not So Much
- Could The Credit Crisis Help Pfizer?
- Biotech Bonanza For ImClone & Dendreon
- Dendreon, ImClone & Pfizer: Your Emails
- Lilly's "Secret" (About ImClone) Is Out--Or Is It?
- Web Extra: Our Kinda' Guy!
- Mad Mail: Is Deere a Buy?
- Lightning Round: Ford, Philip Morris, IBM and More
- Lightning Round OT: AMR, Owens-Illinois and More
- Our Pawnshop Economy
- Executive Decision: Ultra Petroleum CEO Mike Watford
- Washington Fends Off Shorts, Banks Breathe Easy
- Big Bear Playbook
- Pops & Drops: Chesapeake Energy, Pepsi...
- Britain to Cut 10,000 Public Sector Jobs : Report
- Asian Markets Ease on Wall Street Decline
- Intel Shares Rise as Profit Beats Expectations
- Genentech Profit Rises on Strong Drug Sales
- Bank of New York Will Oversee Bailout Fund
- Apple Laptops Get iPhone-Like Trackpad, Lower Price
- New Bailout Package Helps, But More May Be Needed
- Sovereign Funds: No Interest In Rescuing U.S. Firms
- Thriftiness on Special in Aisle 5
Text Size 
 |
Possibly a week from today (Friday) Genentech [DNA
Loading...
()
] could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision. An advisory committee voted 5-4 against recommending approval, but many analysts and investors think the FDA could still say "yes."
The following week Johnson and Johnson [JNJ
Loading...
()
] and Theravance [THRX
Loading...
()
] go before an FDA panel seeking recommendations for approval of their individual new drugs for MRSA--what many have taken to calling the "superbug".
On March 5th Pfizer [PFE
Loading...
()
] is holding a big meeting with analysts and investors. I've made a formal request for an interview there with Chairman and CEO Jeff Kindler. He hasn't done a CNBC interview since November 2006, so we'll see what happens.
MIke's Posts |
March 13th is a big day for Amgen [AMGN
Loading...
()
] and to a lesser extent for JNJ. An FDA panel takes up possibly recommending new restrictions on the use of their embattled anemia drugs for cancer patients dealing with the side effects of chemo.
The day after that Genentech meets with Wall Street in NYC.
And then at the end of March there's the American College of Cardiology conference in Chicago. That's where we're waiting to hear if Merck [MRK
Loading...
()
] and Schering-Plough [SGP
Loading...
()
] will present the controversial data on their cholesterol drug Vytorin.
And that's just what's on the calender. Lately, we've been bombarded by a bunch of unexpected news--i.e. FDA "warnings" about Allergan's Botox and Pfizer's Chantix.
Never a dull moment. Enjoy the three-day weekend.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes